ICER revises sickle cell gene therapy report, preps to dig into what CMS negotiations might look like

The Boston-based In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view, a drug price watch­dog, has re­vised its re­port on sick­le cell gene ther­a­pies and is plan­ning a new re­port this Sep­tem­ber that will eval­u­ate how CMS might ne­go­ti­ate the prices for two block­busters: Bris­tol My­ers Squibb’s Eliquis (apix­a­ban) and Bay­er’s Xarel­to (ri­varox­a­ban).

The two drugs are like­ly to be se­lect­ed for the first year of ne­go­ti­a­tions as part of the In­fla­tion Re­duc­tion Act, along­side oth­ers like Ab­b­Vie’s Im­bru­vi­ca.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN